JMP Securities Reiterates Market Outperform on Werewolf Therapeutics, Maintains $12 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Reni Benjamin has reiterated a Market Outperform rating for Werewolf Therapeutics (NASDAQ:HOWL) and maintained a $12 price target.
June 04, 2024 | 12:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities analyst Reni Benjamin has reiterated a Market Outperform rating for Werewolf Therapeutics and maintained a $12 price target.
The reiteration of a Market Outperform rating and the maintenance of a $12 price target by JMP Securities is a positive signal for investors, likely boosting short-term confidence and potentially driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100